The body’s immune system is supposed to attack invaders, not the liver itself. In autoimmune hepatitis, that wiring goes wrong, and white blood cells start chewing through hepatocytes the way they would a virus. Left untreated, the inflammation can quietly progress to cirrhosis within a few years. Caught early and managed with the right immunosuppressants, most patients live a normal lifespan.
Roughly 100,000 to 200,000 Americans are thought to have the condition, though true prevalence is murky because many cases are diagnosed incidentally during a workup for elevated liver enzymes. Women account for about three out of every four cases, according to the National Institute of Diabetes and Digestive and Kidney Diseases. This guide walks through the two main subtypes, how doctors confirm a diagnosis, and what life on long-term immunosuppression actually looks like.
What Autoimmune Hepatitis Is
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease driven by immune-mediated destruction of liver cells. Unlike viral hepatitis, no infection is involved. Unlike alcohol-related liver disease, drinking is not the trigger. The hallmark on liver biopsy is interface hepatitis, where lymphocytes pile up at the border between the portal tract and the liver lobule.
Hepatologists generally split AIH into two types. Type 1 accounts for about 80 percent of cases and shows up across all age groups, often alongside other autoimmune problems like Hashimoto’s thyroiditis or celiac disease. Type 2 is rarer, tends to strike children and young women, and runs a more aggressive course. Both share the same general treatment playbook, but type 2 patients usually need lifelong therapy. For broader context on immune-mediated diseases, the Medical Conditions guide covers overlapping autoimmune categories.
Causes and Risk Factors
No single cause has been pinned down. Genetic susceptibility plays a role — certain HLA-DR3 and HLA-DR4 alleles raise risk noticeably, especially in people of European descent. Environmental triggers likely tip a genetically primed immune system over the edge. Suspected triggers include hepatitis A and B viruses, Epstein-Barr virus, measles virus, and certain medications such as nitrofurantoin, minocycline, and statins, according to the Mayo Clinic.
Patients with one autoimmune disease tend to collect others. AIH frequently overlaps with primary biliary cholangitis, primary sclerosing cholangitis, type 1 diabetes, vitiligo, and ulcerative colitis. Anyone diagnosed with a related autoimmune disorder — for example, those reading our ulcerative colitis material — should mention any persistent fatigue or right-upper-quadrant discomfort to their gastroenterologist.
Recognizing the Symptoms
About a third of patients have no symptoms at diagnosis. Their disease is found because routine bloodwork shows elevated AST and ALT, sometimes three to ten times the upper limit of normal. Another third walk in with vague complaints: fatigue that does not lift with sleep, joint aches that wander, low-grade nausea, mild itching. The remaining patients present in florid acute hepatitis — jaundice, dark urine, pale stools, abdominal pain over the liver.
A small but important subset present in acute liver failure, with rapid yellowing, confusion (hepatic encephalopathy), and coagulopathy. This is a medical emergency. Children with type 2 AIH are more likely to debut this way than adults with type 1.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience yellowing of the skin or eyes with confusion or excessive sleepiness, vomiting blood, black tarry stools, severe abdominal swelling, or easy bruising and bleeding alongside known liver disease.
How Doctors Diagnose It
There is no single confirmatory test. Diagnosis hinges on a scoring system from the International Autoimmune Hepatitis Group, which weighs autoantibody titers, IgG levels, viral hepatitis exclusion, and biopsy findings. Most workups start with a hepatitis panel to rule out HBV and HCV, then move to autoantibodies: ANA and anti-smooth muscle antibody for type 1, anti-LKM-1 for type 2.
Serum IgG is typically elevated 1.5 to 2 times normal. A liver biopsy remains the gold standard, both to confirm interface hepatitis and to stage fibrosis. According to a review in the Journal of Hepatology, biopsy changes management in roughly a quarter of suspected cases by either confirming overlap syndromes or revealing alternative diagnoses like drug-induced liver injury.
Standard Treatment
The goal is biochemical remission: normalization of AST, ALT, and IgG, plus minimal inflammation on follow-up biopsy. Two drug regimens dominate first-line therapy. The first is prednisone monotherapy, usually starting at 40 to 60 mg daily and tapering over weeks. The second, more common today, combines a lower starting dose of prednisone (about 30 mg) with azathioprine (50 to 150 mg daily), which lets clinicians wean steroids faster and limit long-term side effects.
Roughly 65 to 80 percent of patients reach remission within 18 months. Patients who can’t tolerate azathioprine sometimes switch to mycophenolate mofetil, though this is off-label. Those who fail to respond may move to tacrolimus or cyclosporine. The American Association for the Study of Liver Diseases recommends maintenance for at least three years and at least 24 months of normal labs before any taper attempt.
Living With Long-Term Immunosuppression
Steroids carry their own bill: weight gain, mood swings, blood sugar elevation, bone loss, cataracts, and increased infection risk. Most hepatologists pair long-term prednisone with calcium, vitamin D, and a bone density scan every two years. Azathioprine requires baseline TPMT enzyme testing, since people with low TPMT activity can suffer life-threatening bone marrow suppression at standard doses.
Live vaccines are off the table once on immunosuppressants, but inactivated flu, COVID, pneumococcal, and shingles (Shingrix) shots are encouraged. Patients should avoid raw milk, raw oysters, and undercooked meats. Alcohol, even in moderate amounts, accelerates fibrosis and is generally discouraged. Annual ultrasound surveillance for hepatocellular carcinoma is standard once cirrhosis develops, per Cleveland Clinic guidelines.
Prognosis and Relapse Risk
Patients who reach and maintain biochemical remission have 10-year survival rates above 90 percent — comparable to the general population. Cirrhosis at diagnosis worsens the picture but does not eliminate the chance of remission. About 50 to 80 percent of patients relapse within one to three years of stopping treatment, which is why many hepatologists now favor indefinite low-dose maintenance over repeated taper attempts.
Liver transplantation is reserved for fulminant failure or end-stage cirrhosis. Outcomes are excellent — five-year survival around 80 percent — but AIH can recur in the transplanted liver in up to 30 percent of cases.
When to See a Doctor
Persistent fatigue paired with abnormal liver enzymes on routine labs warrants a workup, not reassurance. Anyone with a personal or family history of autoimmune disease who develops unexplained jaundice, right-upper-quadrant tenderness, or pruritus should request liver function tests. A hepatologist or gastroenterologist with liver expertise is the right specialist; primary care can run initial labs but the diagnostic algorithm and long-term immunosuppression really need a subspecialist.
Frequently Asked Questions
Can autoimmune hepatitis go into remission without medication?
Spontaneous remission is rare and usually transient. Untreated symptomatic AIH carries a five-year mortality near 50 percent in older studies. Modern guidelines recommend treatment for nearly all symptomatic patients and most asymptomatic ones with significant inflammation on biopsy.
Is autoimmune hepatitis the same as fatty liver disease?
No. Non-alcoholic fatty liver disease is driven by metabolic factors like obesity and insulin resistance, while autoimmune hepatitis is immune-mediated. The two can coexist, which sometimes complicates interpretation of liver enzymes and biopsies.
Will I need a liver transplant?
Most patients diagnosed early do not. Fewer than 10 percent of well-managed AIH cases progress to needing transplant. The risk climbs substantially in patients who delay treatment, repeatedly relapse, or were already cirrhotic at diagnosis.
Can pregnancy worsen autoimmune hepatitis?
Disease activity often quiets during pregnancy and flares postpartum. Azathioprine is generally considered compatible with pregnancy under specialist supervision, though mycophenolate is teratogenic and must be stopped well before conception.
The Bottom Line
Autoimmune hepatitis used to be a uniformly grim diagnosis. Today it is a chronic but highly treatable condition for the majority of patients who reach a hepatologist before significant fibrosis sets in. The hard part is recognizing it — vague fatigue and abnormal liver enzymes can sit unexplained for years. If your AST or ALT keeps coming back elevated, push for the autoantibody panel and IgG, and don’t accept “your liver enzymes are a little high” as a final answer.